Bone, fracture and frailty

Current Opinion in HIV and AIDS

Volumn 6, Issue 4, 2011, Pages 309-314

  Hoy, Jennifer ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

fractures; frailty; HIV; low bone mineral density; osteoporosis

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NUCLEOSIDE ANALOG; TENOFOVIR; ZIDOVUDINE;

BODY MASS; BONE DENSITY; BONE FRAGILITY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CROSS-SECTIONAL STUDY; DISEASE COURSE; DUAL ENERGY X RAY ABSORPTIOMETRY; ETHNICITY; FRACTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFESTYLE; LONGITUDINAL STUDY; META ANALYSIS; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK; SURVIVAL; VITAMIN D DEFICIENCY;

ANTI-HIV AGENTS; BONE AND BONES; BONE RESORPTION; COHORT STUDIES; FRACTURES, BONE; HIV INFECTIONS; HUMANS; INCIDENCE; PREVALENCE;

EID: 79959345310     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283478741     Document Type: Review

References (46)

1. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20:2165-2174. (Pubitemid 44684707)
2. Bolland MJ, Grey AB, Gamble GD, Reid IR. CLINICAL Review #: low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab 2007; 92:4522-4528. (Pubitemid 350223420)
3. Knobel H, Guelar A, Vallecillo G, et al. Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS 2001; 15:807-808.
4. Dolan SE, Huang JS, Killilea KM, et al. Reduced bone density in HIV-infected women. AIDS 2004; 18:475-483. (Pubitemid 38365875)
5. Amiel C, Ostertag A, Slama L, et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Mineral Res 2004; 19:402-409. (Pubitemid 38787395)
6. Yin M, Dobkin J, Brudney K, et al. Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteop Int 2005; 16:1345-1352. (Pubitemid 41534646)
7. Arnsten JH, Freeman R, Howard AA, et al. HIV infection andbone mineral density in middle-aged women [see comment]. Clin Infect Dis 2006; 42:1014-1020.
8. Arnsten JH, Freeman R, Howard AA, et al. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007; 21:617-623.
9. Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight preantiretroviral therapy. AIDS 2001; 15:703-709. (Pubitemid 32423217)
10. Bruera D, Luna N, David DO, et al. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003; 17:1917-1923. (Pubitemid 37070277)
11. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003; 36:482-490. (Pubitemid 36241317)
12. Cazanave C, Dupon M, Lavignolle-Aurillac V, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008; 22:395-402.
13. Calmy A, Fux CA, Norris R, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis 2009; 200:1746-1754. Large cohort study showing the insensitivity of FRAX equation using classical risk factors to identify HIV-infected individuals requiring DXA assessment.
14. Mallon PWG. HIV and bone mineral density. Curr Opin Infect Dis 2010; 23:1-8.
15. Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009; 23:817-824.
16. van Vonderen MGA, Lips P, van Agtmael MA, et al. First line zidovudine/ lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 2009; 23:1367-1376.
17. Stellbrink H-J, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51:963-972. A randomized study that shows yet again, greater bone loss of 2.4-3.6% at hip and spine, for those randomized to the tenofovir/emtricitabine arm. This study also found predictors for greater bone loss were lower baseline body mass index, non- Black race and age greater than 45 years. It is the first study to examine markers of bone turnover, showing markers of bone resorption and bone formation both increase by week 12 after initiation of ART.
18. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. J Am Med Assoc 2004; 292:191-201. (Pubitemid 38917996)
19. Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51:554-561.
20. Grund B, Peng G, Gibert CL, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009; 23:1519-1529.
21. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49:1591-1601.
22. Yin MT, McMahon DJ, Ferris DC, et al. Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2010; 95:620-629. One of several important studies from the WIHS cohort examining multiple aspects of bone health in postmenopausal women, including bone turnover markers.
23. Yin MT, Lu D, Cremers S, et al. Short-term bone loss in HIVinfected premenopausal women. J Acquir Immune Defic Syndr 2010; 53:202-208.
24. Libois A, Clumeck N, Kabeya K, et al. Risk factors of osteopenia in HIV-infected women: no role of antiretroviral therapy. Maturitas 2010; 65:51-54.
25. Grijsen ML, Vrouenraets SME, Steingrover R, et al. High prevalence of reduced bone mineral density in primary HIV-1-infected men. AIDS 2010; 24:2233-2238. Interesting study reporting acute bone loss during HIV seroconversion.
26. Jacobson DL, Lindsey JC, Gordon CM, et al. Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. AIDS 2010; 24:687-696. An important evaluation of bone changes during puberty with a comparison with uninfected adolescents according to stage of sexual maturity rather than age.
27. Zuccotti G, Vigano A, Gabiano C, et al. Antiretroviral therapy and bone mineral measurements in HIV-infected youths. Bone 2010; 46:1633-1638.
28. Vigano A, Zuccotti GV, Puzzovio M, et al. Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths. Antivir Ther 2010; 15:1053-1058.
29. Jones S, Restrepo D, Kasowitz A, et al. Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteop Int 2008; 19:913-918.
30. Onen NF, Overton ET, Seyfried W, et al. Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials 2010; 11:100-109.
31. Sharma A, Flom PL, Weedon J, Klein RS. Prospective study of bone mineral density changes in aging men with or at risk for HIV infection. AIDS 2010; 24:2337-2345.
32. Degris E, Delpierre C, Sommet A, et al. Longitudinal study of body composition of 101 HIV men with lipodystrophy: dual-energy X-ray criteria for lipodystrophy evolution. J Clin Densitometry 2010; 13:237-244.
33. Dao CN, Patel P, Overton ET, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011; 52:396-405. Rates of vitamin D deficiency are no different between HIV-infected individuals and the general population, and no association between vitamin D deficiency and BMD was noted in this study.
34. Stein EM, Yin MT, McMahon DJ, et al. Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women. Osteop Int 2011;22:477-487.
35. Rodriguez M, Daniels B, Gunawardene S, Robbins GK. High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Res Hum Retroviruses 2009; 25:9-14.
36. Childs KE, Fishman SL, Constable C, et al. Short communication: inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses 2010; 26:855-859.
37. Paul TV, Asha HS, Thomas N, et al. Hypovitaminosis D and bone mineral density in human immunodeficiency virus-infected men from India, with or without antiretroviral therapy. Endocrine Pract 2010; 16:547-553.
38. van den Bout-van den Beukel CJP, van den Bos M, Oyen WJG, et al. The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D-deficient HIV-1-infected patients. HIV Med 2008; 9:771-779.
39. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93:3499-3504.
40. Yin MT, Shi Q, Hoover DR, et al. Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study. AIDS 2010; 24:2679-2686. Data from the WIHS report no difference in fracture prevalence for premenopausal women.
41. Collin F, Duval X, Le Moing V, et al. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS 2009; 23:1021-1024.
42. Gazzola L, Comi L, Savoldi A, et al. Use of the FRAX equation as first-line screening of bone metabolism alteration in the HIV-infected population. J Infect Dis 2010; 202:330-331; author reply 1-2.
43. Desquilbet L, Jacobson LP, Fried LP, et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol Ser A Biol Sci Med Sci 2007; 62:1279-1286. (Pubitemid 350287617)
44. Desquilbet L, Margolick JB, Fried LP, et al. Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men. J Acquir Immune Defic Syndr 2009; 50:299-306.
45. Onen NF, Agbebi A, Shacham E, et al. Frailty among HIV-infected persons in an urban outpatient care setting. J Infect 2009; 59:346-352.
46. Terzian AS, Holman S, Nathwani N, et al. Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART. J Women's Health 2009; 18:1965-1974. Important study investigating prevalence and predictors of frailty in HIV-infected women.